ProQR Therapeutics (NASDAQ:PRQR) Director Acquires 150,000 Shares of Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius purchased 150,000 shares of the stock in a transaction dated Friday, July 17th. The shares were acquired at an average price of $1.72 per share, with a total value of $258,000.00. Following the transaction, the director owned 300,000 shares in the company, valued at $516,000. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bart Filius also recently made the following trade(s):

• On Friday, June 26th, Bart Filius acquired 150,000 shares of ProQR Therapeutics stock. The stock was acquired at an average price of $1.54 per share, for a total transaction of $231,000.00.

ProQR Therapeutics Stock Down 0.3%

PRQR stock traded down $0.01 during midday trading on Tuesday, reaching $1.73. The company’s stock had a trading volume of 229,868 shares, compared to its average volume of 713,946. The business’s 50-day simple moving average is $1.65 and its 200-day simple moving average is $1.65. ProQR Therapeutics N.V. has a 52 week low of $1.33 and a 52 week high of $3.10. The stock has a market cap of $181.75 million, a PE ratio of -3.45 and a beta of 0.04.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%.The company had revenue of $2.35 million for the quarter, compared to the consensus estimate of $5.19 million. As a group, equities analysts forecast that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PRQR. Chardan Capital dropped their price objective on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Wall Street Zen lowered ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. JonesTrading decreased their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Weiss Ratings lowered ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.33.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Privium Fund Management B.V. increased its holdings in ProQR Therapeutics by 7.2% in the 4th quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after buying an additional 359,475 shares during the period. Aberdeen Group plc increased its position in ProQR Therapeutics by 28.4% during the 4th quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock valued at $5,960,000 after purchasing an additional 651,853 shares during the period. Ikarian Capital LLC lifted its position in shares of ProQR Therapeutics by 67.2% in the 4th quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after purchasing an additional 600,000 shares during the period. Citadel Advisors LLC boosted its stake in shares of ProQR Therapeutics by 73.2% in the 3rd quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock valued at $1,399,000 after purchasing an additional 277,749 shares during the last quarter. Finally, Walleye Capital LLC raised its stake in ProQR Therapeutics by 2.7% during the first quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock worth $984,000 after buying an additional 15,744 shares during the last quarter. 32.65% of the stock is owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.